Beyond anemia: Red cell distribution width as a universal biomarker in contemporary medicine

Red cell distribution width (RDW), traditionally employed as a parameter for classifying anemia, has undergone a remarkable transformation in clinical medicine to emerge as a powerful prognostic biomarker across an extensive spectrum of pathological conditions. This comprehensive review meticulously examines RDW’s extraordinary evolution from its conventional role in hematology to its current standing as a versatile clinical indicator with broad applicability. A significant advantage of RDW is its automatic calculation by modern automated hematology analyzers as part of routine complete blood counts, rendering it exceptionally accessible and cost-effective as a biomarker in clinical settings worldwide. The complex pathophysiological mechanisms linking elevated RDW to various disease states involve sophisticated interactions between inflammatory cascades, oxidative stress pathways, nutritional deficiencies, bone marrow dysfunction, and metabolic dysregulations. The growing body of evidence supporting RDW’s clinical utility extends across multiple medical specialties, including cardiovascular medicine, hepatology, gastroenterology, endocrinology, pulmonology, infectious diseases, rheumatology, neurology, nephrology, and oncology. Despite its demonstrated broad applicability, significant challenges in standardization and interpretation persist, necessitating further research. Future investigative directions are focused on establishing disease-specific thresholds, integrating RDW into existing risk prediction models, and elucidating the molecular mechanisms that connect RDW elevation to pathological processes. As our understanding continues to deepen, RDW demonstrates exceptional promise for developing personalized approaches to disease monitoring and prognostication, firmly establishing its position as an invaluable tool in contemporary clinical practice.